Viracta Therapeutics Inc VIRX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/13/24 EDT
0.771quote price arrow up+0.011 (+1.4475%)
Volume
39,477
52 week range
0.43 - 2.38
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.771
  • 52 Week High2.38
  • 52 Week High Date05/22/23
  • 52 Week Low0.43
  • 52 Week Low Date12/19/23

Key Stats

  • Market Cap30.279M
  • Shares Out39.27M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta0.76
  • YTD % Change35.26

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.771
  • 52 Week High2.38
  • 52 Week High Date05/22/23
  • 52 Week Low0.43
  • 52 Week Low Date12/19/23
  • Market Cap30.279M
  • Shares Out39.27M
  • 10 Day Average Volume0.05M
  • Dividend-
  • Dividend Yield-
  • Beta0.76
  • YTD % Change35.26

RATIOS/PROFITABILITY

  • EPS (TTM)-1.23
  • P/E (TTM)-0.62
  • Fwd P/E (NTM)-0.64
  • EBITDA (TTM)-51.882M
  • ROE (TTM)-187.14%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-18,008.33%
  • Debt To Equity (MRQ)168.57%

EVENTS

  • Earnings Date08/12/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Viracta Therapeutics Inc

 

Profile

MORE
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter...
Roger Pomerantz M.D.
Independent Chairman of the Board
Mark Rothera
President, Chief Executive Officer, Director
Melody Burcar CPA
Interim Principal Financial Officer and Interim Principal Accounting Officer
Address
2533 S COAST HWY 101, SUITE 210
Cardiff By The Sea, CA
92007
United States

Top Peers

SYMBOLLASTCHG%CHG
NGNE
Neurogene Inc
30.64-1.86-5.72%
ACHL
Achilles Therapeutics PLC
0.8898-0.0503-5.3505%
ENLV
Enlivex Therapeutics Ltd
1.46-0.04-2.67%
INKT
Mink Therapeutics Inc
0.9798+0.0798+8.8667%
CNTX
Context Therapeutics Inc
1.68-0.19-10.16%